Premium
Pharmacological profile of PD 117302, a selective κ‐opioid agonist
Author(s) -
Leighton G.E.,
Johnson M.A.,
Meecham K.G.,
Hill R.G.,
Hughes J.
Publication year - 1987
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1987.tb11398.x
Subject(s) - agonist , pharmacology , opioid , chemistry , (+) naloxone , opioid receptor , noxious stimulus , nociception , morphine , opioid antagonist , receptor , medicine , biochemistry
1 PD 117302, a new nonpeptide opioid compound shown in in vitro studies to be a selective κ‐opioid agonist, has been evaluted in vivo for antinociceptive activity and other effects characteristic of κ‐receptor activation. 2 Dose‐related long lasting antinociception was produced by PD 117302 against a mechanical noxious stimulus in rats following intravenous, subcutaneous or oral administration. 3 PD 117302 was effective in raising the nociceptive threshold to mechanical and chemical but not to thermal noxious stimuli in the mouse. This effect was attenuated in animals pretreated with the opioid antagonist naloxone. 4 In addition to producing antinociception, PD 117302 also caused naloxone‐reversible locomotor impairment and diuresis, effects that are typical of κ‐agonists. 5 PD 117302 did not cause respiratory depression, inhibition of gastrointestinal motility or naloxone‐precipated withdrawal jumping in mice, effects that are associated with actions at the μ‐opioid receptor. 6 The pharmacological profile of PD 117302 in vivo is consistent with in vitro data suggesting that PD 117302 is a selective agonist at the κ‐opioid receptor.